Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Rahul Raj Aggarwal,Owen Witte,Pamela Paris,Alexandria Toschi,Nicole Zona,Jack Youngren,Primo Lara,Susan Olson,Charles J Ryan,Adam Foye,Robert Evan Reiter,Christopher P Evans,George Thomas,Kim N Chi,Tomasz M Beer,Josh Stuart,Martin Edwin Gleave,Eric Jay Small,Joshi J Alumkal

doi:10.1200/jco.2015.33.15_suppl.5068

Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Rahul Raj Aggarwal, Owen Witte + Show 17 more

https://doi.org/10.1200/jco.2015.33.15_suppl.5068

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2015
Citations: 5

Affiliation: University of California, San Francisco, UCLA Health, University of California, Davis, Oregon Health & Science University, Santa Cruz County Office of Education, University of California, Santa Cruz, University of Portland

#Androgen Receptor Amplification #West Coast Prostate Cancer Dream + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

5068 Background: Mechanisms of resistance to Abi or Enz in mCRPC pts are poorly understood. AR amplification (AR amp) is observed in Abi/Enz naive mCRPC pts, but its role in mCRPC pts who develop r...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.